Antibiotics in the prevention and treatment of coronary heart disease.
Seroepidemiology, pathology, and animal studies provide evidence for a possible association between Chlamydia pneumoniae infections and atherosclerosis, coronary heart disease, and myocardial infarction. If this association exists, then exposure to certain antibiotics may positively affect the clinical course after an acute ischemic cardiac event (secondary prevention) and affect the risk of developing a first-time myocardial infarction (primary prevention). Preliminary evidence from clinical trials suggests that treatment with new macrolide antibiotics may improve outcome after ischemic events, and evidence from a large case-control analysis indicates that exposure to tetracyclines or quinolones may reduce the risk of developing a first-time myocardial infarction. However, antibiotics for the treatment or prevention of ischemic heart disease must not be recommended yet. This review of published studies briefly summarizes the currently available literature on the effects of antibiotics on the risk of developing coronary heart disease and myocardial infarction.
Meier
C R
CR
Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacology, Dept. of Internal Medicine, University Hospital, 4031 Basel, Switzerland. Christoph.Meier@unibas.ch
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003327:Coronary Disease / Q000188:drug therapy* / Q000517:prevention & control*; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic
D000900:Anti-Bacterial Agents